SII gets approval for the creation of a vaccine against the omicron type


Posted on 07 February 2022


For Illustration Purpose Only.

Official sources claimed on Monday that the Drugs Controller General of India (DCGI) had accepted Serum Institute of India's proposal to create a vaccine against the omicron type of coronavirus for investigation, testing, and analysis. Prakash Kumar Singh, the SII's Director of Government and Regulatory Affairs, filed an application with the DCGI on January 6 stating that the Pune-based firm is working on the development of an omicron vaccine in collaboration with Novavax Inc, according to an official source, and that the SII has obtained permission and license to manufacture SARS-CoV-2rS drug substance for examination, test, and analysis.


Key Points


  • Official sources claimed on Monday that the Drugs Controller General of India (DCGI) had accepted Serum Institute of India's proposal to create a vaccine against the omicron type of coronavirus for investigation, testing, and analysis.

  • Prakash Kumar Singh, the SII's Director of Government and Regulatory Affairs, filed an application with the DCGI on January 6 stating that the Pune-based firm is working on the development of an omicron vaccine in collaboration with Novavax Inc, according to an official source.

Follow Us On Google Newsstand: Click Here